专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

AU2002327182B2 Novel heterocyclic antibacterial compounds 未知
公开(公告)号：AU2002327182B2
公开(公告)日：2005-09-15
申请号：AU2002327182
申请日：2002-06-17
申请人： MICROBIOTIX INC
发明人： ZHI CHENGXIN , WRIGHT GEORGE E
IPC分类号： A61K31/185 , A61K31/4709 , A61K31/513 , A61K31/519 , A61K31/5383 , A61K45/06 , A61P31/04 , A61P43/00 , C07D401/12 , C07D401/14 , C07D471/04 , C07D487/04 , C07D498/04 , A61K031/185 , A61K031/4709 , A61P031/04

2. 发明专利

AU2001258061B2 Novel antibiotic compounds 未知
公开(公告)号：AU2001258061B2
公开(公告)日：2005-09-29
申请号：AU2001258061
申请日：2001-05-22
申请人： COMMW SCIENT IND RES ORG
发明人： TROWELL STEPHEN CHARLES , RICKARDS RODNEY WARREN , ZHAO CHUNJIU
IPC分类号： A61K31/015 , A61K31/045 , A61K31/047 , A61K31/185 , A61L2/18 , A61P31/04 , A61P31/06 , A61P31/08 , C07C13/573 , C07C013/573 , A61K031/015 , A61K031/045 , A61K031/047 , A61K031/185 , A61L002/18 , A61P031/04 , A61P031/06 , A61P031/08

3. 发明申请

US20040209847A1 Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses 有权
标题翻译：用于胆固醇管理和相关用途的环烷基 - 羟基化合物和组合物
公开(公告)号：US20040209847A1
公开(公告)日：2004-10-21
申请号：US10743287
申请日：2003-12-23
发明人： Jean-Louis Henri Dasseux , Carmen Daniela Oniciu
IPC分类号： A61K031/66 , A61K031/366 , A61K031/365 , A61K031/335 , A61K031/185
CPC分类号： C07C31/27 , A61K31/191 , A61K31/194 , A61K31/20 , A61K31/23 , C07C31/20 , C07C31/22 , C07C31/24 , C07C33/26 , C07C47/19 , C07C47/34 , C07C59/01 , C07C59/105 , C07C59/11 , C07C59/245 , C07C59/285 , C07C59/29 , C07C59/46 , C07C59/48 , C07C59/54 , C07C61/12 , C07C62/02 , C07C62/06 , C07C65/17 , C07C69/003 , C07C69/017 , C07C69/675 , C07C69/757 , C07C255/00 , C07C309/08 , C07C309/24 , C07C309/25 , C07C2101/02 , C07C2101/04 , C07C2101/08 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07D213/80 , C07D257/04 , C07D261/08 , C07D261/12 , C07D305/12 , C07D307/33 , C07D309/10 , C07D309/12 , C07D309/30 , C07D405/12 , C07D495/04 , C07F9/093 , C07F9/094 , C07F9/11 , C07F9/117 , C07F9/12 , C07F9/2408 , C07F9/2416 , C07F9/242 , C07F9/2425 , C07F9/4423
摘要： The present invention relates to novel cycloalkyl-hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, Syndrome X, thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.
摘要翻译：本发明涉及新的环烷基 - 羟基化合物，包含羟基化合物的组合物和可用于治疗和预防各种疾病和病症例如但不限于老化，阿尔茨海默氏病，癌症，心血管疾病，糖尿病性肾病，糖尿病视网膜病变，葡萄糖代谢紊乱，血脂异常，脂蛋白血症，高血压，阳ence，炎症，胰岛素抵抗，胆汁中的脂质消除，肥胖，胆汁中的氧固醇消除，胰腺炎，帕金森病，过氧化物酶体增殖物激活受体相关病症，磷脂消除胆汁，肾脏疾病，败血症，X综合征，血栓形成障碍。本发明的化合物和方法也可用于调节C反应蛋白或增强患者的胆汁产生。在某些实施方案中，本发明的化合物，组合物和方法可用于与其它治疗剂如降胆固醇和降血糖药物组合治疗。

4. 发明申请

US20040198819A1 Biological response modifier composition and uses thereof 审中-公开
标题翻译：生物反应调节剂组合物及其用途
公开(公告)号：US20040198819A1
公开(公告)日：2004-10-07
申请号：US10481867
申请日：2004-05-03
发明人： Aiping H. Young
IPC分类号： A61K031/185 , A61K031/19 , A61K031/198 , A61K031/17
CPC分类号： A61K31/198 , A61K31/14 , A61K31/17 , A61K31/185 , A61K31/19 , A61K31/197 , A61K31/205 , A61K31/4168 , A61K2300/00
摘要： The present invention provides synthetic biological response modifier compositions. The synthetic biologic response modifier (Syn-BRM) composition comprises: 57null20 mg/L 3-hydroxybutyric acid, 125null44 mg/L lactic acid, 155null54 mg/L acetic acid, 1.4null0.5 mg/L creatine, 22null8 mg/L creatinine, 2.5null0.9 mg/L carnitine, 6.8null2.4 mg/L taurine, 20null7 mg/L choline, 815null285 mg/L urea. The compositions may additionally comprise 40null14 mg/L of formic acid. The synthetic biological response modifier compositions modify biological response in vivo demonstrating anti-cancer activity and enhancing cell-mediated immune response to tumours. The invention further provides anticancer combinations comprising a synthetic biological response modifier composition and one or more anticancer agents, wherein said combination improves the treatment of cancers over the composition or the anticancer agents alone. Another aspect of the present invention provides the use of synthetic biological response modifier compositions or an anticancer combination thereof in the manufacture of a medicament or a pharmaceutical kit and in the treatment of cancer.
摘要翻译：本发明提供合成的生物反应调节剂组合物。合成生物反应调节剂（Syn-BRM）组成包括：57±20mg / L 3-羟基丁酸，125±44mg / L乳酸，155±54mg / L乙酸，1.4±0.5mg / L肌酸， 22±8mg / L肌酸酐，2.5±0.9mg / L肉碱，6.8±2.4mg / L牛磺酸，20±7mg / L胆碱，815±285mg / L尿素。组合物可另外包含40±14mg / L的甲酸。合成的生物反应调节剂组合物改变体内的生物反应，证明抗癌活性并增强细胞介导的对肿瘤的免疫应答。本发明还提供包含合成生物反应调节剂组合物和一种或多种抗癌剂的抗癌组合，其中所述组合改善了对组合物或抗癌剂单独治疗癌症。本发明的另一方面提供了合成生物反应调节剂组合物或其抗癌组合在制备药物或药物试剂盒中以及用于治疗癌症中的用途。

5. 发明申请

US20040138300A1 Compounds 失效
标题翻译：化合物
公开(公告)号：US20040138300A1
公开(公告)日：2004-07-15
申请号：US10475054
申请日：2003-10-17
发明人： Krister Bamberg , Lanna Li
IPC分类号： A61K031/277 , A61K031/185 , A61K031/195
CPC分类号： C07C217/60 , C07C271/28 , C07C279/18 , C07C279/24
摘要： The present invention releates to certain novel guanidine or amidine acid derivatives and analogs, to a process for preparing such compounds, having the utility in clinical conditions associated with insulin resistance, to methods for their therapeutic use and to pharmaceutical compositions containing them.
摘要翻译：本发明涉及某些新颖的胍或脒酸衍生物和类似物，涉及一种制备此类化合物的方法，其具有与胰岛素抵抗相关的临床病症的用途，其治疗用途的方法和含有它们的药物组合物。

6. 发明申请

US20040127558A1 Sodium dodecyl sulfate compositions for inactivating prions 审中-公开
公开(公告)号：US20040127558A1
公开(公告)日：2004-07-01
申请号：US10735140
申请日：2003-12-12
申请人： The Regents of the University of California
发明人： Stanley B. Prusiner , Surachai Supattapone
IPC分类号： A61K031/255 , A61K031/185
CPC分类号： A01N25/30 , A01N41/02 , A61K31/185 , A61L2/0088 , A61L2/18 , C11D1/146 , C11D3/48 , G01N2800/2828
摘要： An antiseptic composition useful in destroying the infectivity of infectious proteins such as prions is disclosed. The antiseptic composition is preferably maintained at either a low pH of 4.0 or less or a high pH of 10.0 or more either of which allows for an environment under which the active component (which is preferably sodium dodecyl sulfate) destroys infectivity. The composition may be added to blood, blood products, collagen, tissues and organs prior to transplantation. The composition also may be added to livestock feed to denature any prions in the livestock. Methods of denaturing infectious proteins are also disclosed which method can use but do not require higher temperatures and long period of exposure.

7. 发明申请

US20040120983A1 Nutritional supplement 审中-公开
标题翻译：营养补品
公开(公告)号：US20040120983A1
公开(公告)日：2004-06-24
申请号：US10326946
申请日：2002-12-23
发明人： Philip Connolly
IPC分类号： A61K031/7012 , A61K031/198 , A61K031/70 , A61K031/715 , A61K031/185
CPC分类号： A61K45/06 , A23L29/30 , A23L33/125 , A23L33/175 , A23V2002/00 , A61K31/00 , A61K31/4415 , A61K2300/00 , A23V2250/7052 , A23V2250/062 , A23V2250/306 , A23V2250/0628 , A23V2250/0616 , A23V2250/0606 , A23V2250/60 , A23V2250/061 , A23V2250/0622 , A23V2250/0644
摘要： A nutritional supplement for sports nutrition and also as a general population dietary supplement for aging people is provided. The nutritional supplement is a combination of a high glycemic sugar or carbohydrate, vitamin B6, electrolytic minerals, and amino acids some of which have neuromodulating properties and some of which are muscle cell volumizers. The amino acids included in the nutritional supplement include the amino acids include glutamine, taurine, creatine, cysteine, glycine, leucine, and arginine. The amino acids having neuromodulating properties is chosen from the group consisting of glutamine, taurine, glycine, and cysteine, and combinations thereof. The amino acids having cell volumizing properties is chosen from the group consisting of creatine, taurine, and glycine, and combinations thereof. The combination of the ingredients has a synergistic effect of increasing muscle mass, increasing physical abilities (strength, stamina, and endurance), and decreasing body fat.
摘要翻译：提供运动营养的营养补充剂以及老年人的普通人口膳食补充剂。营养补充剂是高血糖或碳水化合物，维生素B6，电解矿物质和氨基酸的组合，其中一些具有神经调节性质，其中一些是肌肉细胞体积增加剂。包括在营养补充剂中的氨基酸包括氨基酸包括谷氨酰胺，牛磺酸，肌酸，半胱氨酸，甘氨酸，亮氨酸和精氨酸。具有神经调节特性的氨基酸选自谷氨酰胺，牛磺酸，甘氨酸和半胱氨酸及其组合。具有细胞体积特性的氨基酸选自肌酸，牛磺酸和甘氨酸及其组合。这些成分的组合具有增加肌肉质量，增加身体能力（强度，耐力和耐力）以及减少体脂肪的协同效应。

8. 发明申请

US20040034030A1 Formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus 失效
标题翻译：预防和治疗胰岛素抵抗和2型糖尿病的制剂
公开(公告)号：US20040034030A1
公开(公告)日：2004-02-19
申请号：US10630436
申请日：2003-07-30
申请人： ChronoRX LLC
发明人： Kenneth T. Richardson , Don C. Pearson
IPC分类号： A61K031/525 , A61K031/385 , A61K031/375 , A61K031/185 , A61K031/198
CPC分类号： A61K45/06 , A61K31/198 , A61K31/375 , A61K31/385 , A61K31/525 , A61K2300/00
摘要： The compositions and dosage forms of the invention are clinically useful as methods for increasing the effectiveness, efficiency and safety of biguanides (metformin) and/or sulfonylureas in the prevention and treatment of insulin resistance and diabetes mellitus, alone or in combination, as a nutrient for humans. The carefully chosen active ingredients of the invention are designed in a modular fashion to prevent and rectify adverse events associated with insulin resistance syndrome and diabetes mellitus, and with the clinical use of biguanides (metformin) and/or the sulfonylureas. These modules are: (1) Mitochondrial Metabolic Group, (2) Plasma and Mitochondrial Membrane Integrity Group, (3) Nocturnal Group and, (4) Insulin Alternative Group. When used in concert with a biguanide, a sulfonylurea or with a combination of both, the invention will broaden the clinical usefulness of these drugs. The invention will retard the progression of insulin resistance to type 2 diabetes, and reduce the serious microvascular and macrovascular complications commonly associated with insulin resistance syndrome and diabetes mellitus.
摘要翻译：本发明的组合物和剂型在临床上可用作增加双胍（二甲双胍）和/或磺酰脲在预防和治疗胰岛素抵抗和糖尿病中作为营养素单独或组合的有效性，有效性和安全性的方法对于人类精心挑选的本发明的活性成分以模块化方式设计，以防止和纠正与胰岛素抵抗综合征和糖尿病相关的不良事件，以及临床使用双胍（二甲双胍）和/或磺酰脲类。这些模块是：（1）线粒体代谢组，（2）血浆和线粒体膜完整性组，（3）夜间组和（4）胰岛素替代组。当与双胍，磺酰脲或两者结合使用时，本发明将扩大这些药物的临床用途。本发明将阻止胰岛素抵抗2型糖尿病的进展，并减少通常与胰岛素抵抗综合征和糖尿病相关的严重微血管和大血管并发症。

9. 发明申请

US20040002478A1 Ligands for metabotropic glutamate receptors and inhibitors of NAALADase 有权
标题翻译：代谢型谷氨酸受体配体和NAALADase抑制剂
公开(公告)号：US20040002478A1
公开(公告)日：2004-01-01
申请号：US10374765
申请日：2003-02-25
发明人： Alan P. Kozikowski , Jarda T. Wroblewski , Fajun Nan
IPC分类号： A61K031/675 , C07F009/28 , C07D249/16 , A61K031/185 , A61K031/195
CPC分类号： C07D257/04 , C07C59/347 , C07C69/716 , C07C271/22 , C07C275/16 , C07C275/26 , C07C323/59 , C07C335/08 , C07F9/301 , C07F9/303
摘要： The present invention relates to novel compounds and formulations thereof which compounds are ligands, e.g., agonists or antagonists, for a metabotropic glutamate receptor or a NAALADase enzyme or both. The present invention also relates to methods of modulating the activity of a metabotropic glutamate receptor or a NAALADase enzyme or both, e.g., in a subject in need thereof, using a compound or formulation of the present invention. The present invention also relates to methods of treating a subject suffering from a chronic or acute disease, malady or condition due at least in part to an abnormality in the activity of an endogenous metabotropic glutamate receptor or a NAALADase enzyme or both, using a compound or formulation of the present invention.
摘要翻译：本发明涉及其化合物是代谢型谷氨酸受体或NAALADase酶或两者的配体，例如激动剂或拮抗剂的新化合物及其制剂。本发明还涉及使用本发明的化合物或制剂调节代谢型谷氨酸受体或NAALADase酶或两者的活性的方法，例如在有需要的受试者中。本发明还涉及使用化合物或至少部分由内源性代谢型谷氨酸受体或NAALADase酶或两者的活性异常而治疗患有慢性或急性疾病，疾病或病症的受试者的方法，本发明的制剂。

10. 发明申请

US20030207940A1 HYPERICIN AND HYPERICUM EXTRACT: SPECIFIC T-TYPE CALCIUM CHANNEL BLOCKER, AND THEIR USE AS T-TYPE CALCIUM CHANNEL TARGETED THERAPEUTICS 有权
标题翻译： HYPERICIN和HYPERICUM EXTRACT：特异性T型钙通道阻断剂，并被用作T型钙通道靶向治疗
公开(公告)号：US20030207940A1
公开(公告)日：2003-11-06
申请号：US09481572
申请日：2000-01-11
发明人： JACQUELINE J. SHAN , XI-CHEN WU , PETER K. T. PANG , LEI LING
IPC分类号： A61K031/235 , A61K031/185 , A61K031/192 , A61K035/78 , A61K031/12
CPC分类号： A61K31/235 , A61K31/12 , A61K31/185 , A61K31/192 , A61K36/38
摘要： Hypericin has been shown to specifically inhibited T-type calcium channel activity. Hypericum extract containing hypericin also inhibited T-type calcium channel activity. Moreover, other chemicals in Hypericum extract showed a synergistic effect to hypericin. In view of this, hypericin or hypericin-containing Hypericum extract can be used as T-channel blockers. Hypericum extract, extract of other species of the Hypericum genus, extract of other plants containing hypericin, hypericin, hypericin derivatives, hypericin analogs, such as pseudohypericin, and other hypericum extract constituents can be used as therapeutics targeted at T-type calcium channels for treatment of diseases associated with T-channel abnormality. Methods for administering hypericin and hypericum extract are disclosed.
摘要翻译：已显示金丝桃素特异性抑制T型钙通道活性。含金丝桃素的金丝桃提取物也抑制T型钙通道活性。此外，金丝桃提取物中的其他化学物质显示出对金丝桃素的协同作用。鉴于此，金丝桃素或含金丝桃酸的金丝桃提取物可用作T通道阻断剂。金丝桃提取物，金丝桃属的其他物种的提取物，含有金丝桃素的金丝桃素，金丝桃素，金丝桃素衍生物，金丝桃素类似物例如假倍他辛和其他金丝桃提取物成分的提取物可用作靶向T型钙通道的治疗剂用于治疗的与T通道异常相关的疾病。公开了金丝桃素和金丝桃提取物的施用方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式